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AbstrAct
The poor prognosis for patients with inflammatory breast cancer (IBC) compared 
to patients with other types of breast cancers emphasizes the need to better 
understand the molecular underpinnings of this disease with the goal of developing 
effective targeted therapeutics. Dysregulation of matriptase expression, an epithelial-
specific member of the type II transmembrane serine protease family, has been 
demonstrated in many different cancer types. To date, no studies have assessed the 
expression and potential pro-oncogenic role of matriptase in IBC. We examined the 
functional relationship between matriptase and the HGF/c-MET signaling pathway in 
the IBC cell lines SUM149 and SUM190, and in IBC patient samples. Matriptase and 
c-Met proteins are localized on the surface membrane of IBC cells and their expression 
is strongly correlated in infiltrating cancer cells and in the cancer cells of lymphatic 
emboli in patient samples. Abrogation of matriptase expression by silencing with 
RNAi or inhibition of matriptase proteolytic activity with a synthetic inhibitor impairs 
the conversion of inactive pro-HGF to active HGF and subsequent c-Met-mediated 
signaling, leading to efficient impairment of proliferation and invasion of IBC cells. 
These data show the potential of matriptase inhibitors as a novel targeted therapy 
for IBC, and lay the groundwork for the development and testing of such drugs.
IntroductIon
Inflammatory breast cancer (IBC) is a rare and 
aggressive form of invasive breast cancer accounting for 
2–4%, or about 4,000 breast cancer cases annually in the 
United States. IBC is characterized by rapid progression, 
local and distant metastases, younger age of onset, and 
lower overall survival compared with other breast 
cancers, with a 5-year survival rate of 25–40% when 
treated with neoadjuvant chemotherapy, mastectomy, 
and postmastectomy radiation. IBC patients often 
present with a breast that looks inflamed due to extensive 
lymphovascular invasion of tumor emboli which block 
lymphatic drainage from the breast, but no palpable tumor. 
The rapid development of metastases in IBC results from 
high proliferative rates and potent ability for angiogenesis 
and lymphangiogenesis. Furthermore, 20–40% of IBC 
cases are triple-negative breast cancers (TNBC) which 
excludes hormone therapy and HER2 targeting as 
treatment options [1–3].
                   Research Paper
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 Matriptase is an epithelial-specific member of 
the type II transmembrane serine protease family and 
dysregulation of matriptase has been demonstrated in 
many different cancer types [4–7]. Extracellular proteases 
have long been associated with cancer progression 
because of their ability to degrade extracellular matrices, 
which promotes invasion and metastasis. This view 
has been expanded with the findings that proteolysis 
regulates multiple steps of tumor progression including 
proliferation, differentiation, apoptosis, and invasion. One 
concept in protease mechanistic research is that proteolytic 
modifications of targets, including activation of growth 
factors, are critically involved in carcinogenesis through 
activation of oncogenic signaling pathways. 
The pro-form of the hepatocyte growth factor 
(pro-HGF) requires specific proteolytic cleavage to 
be biologically active. HGF is the ligand of the proto-
oncogene receptor tyrosine kinase, c-Met, and when 
matriptase-cleaved HGF is bound to its receptor, the 
activated signaling pathway elicits downstream pro-
tumorigenic events including cell proliferation, migration, 
morphogenesis, and invasion [8–12]. To date, no published 
studies have assessed the expression and potential pro-
cancerous role of the matriptase/HGF/c-Met signaling axis 
in IBC. Here, we present evidence that matriptase may be 
considered a novel therapeutic target for IBC. 
results
correlation between matriptase and c-Met 
expression in Ibc patient samples 
Matriptase and c-Met are cell surface proteins 
that are primarily expressed in epithelial cells. We 
hypothesized that a prerequisite for matriptase and c-Met 
to be functionally linked in vivo is that they are expressed 
in close proximity to each other, on either the same cell 
or neighboring cells. Therefore, an important component 
to elucidate the roles of matriptase and c-Met in IBC is to 
determine their expression and localization in IBC patient 
samples and IBC cultured cells. To ensure specific staining 
in immunohistochemistry (IHC), we used antibodies that 
we had previously validated [7]. Another transmembrane 
protein expressed on the surface of cancer cells, 
E-cadherin, is believed to function as a tumor suppressor 
in some invasive breast carcinomas and its expression is 
frequently lost during cancer progression. Interestingly, 
it has been observed that E-cadherin is retained in the 
majority of IBC cases [19–21]. To assess whether a 
similar E-cadherin expression profile is observed in our 
sample collection, we performed parallel E-cadherin IHC. 
Of the 22 IBC patient samples analyzed, the majority 
(17/22, 77%) displayed expression of matriptase, c-Met, 
and E-cadherin in infiltrating cancer cells and in the 
cancer cells of peritumoral and dermal lymphatic emboli 
(Figure 1 and Supplementary Figure S1). Information 
about patient samples can be found in “Materials and 
Methods” and in Table 1. Furthermore, the staining 
patterns for all three proteins were strikingly similar, 
consistent with co-localization of the protease, the growth 
factor receptor, and the adherens junction protein in IBC 
(Figure 1). No significant staining was observed in tumor 
stromal compartments. Samples from four patients (18%) 
expressed both matriptase and E-cadherin but not c-Met, 
whereas one sample expressed no detectable matriptase, 
c-Met or E-cadherin. Importantly, the vast majority (21/22, 
95%) of the samples retained E-cadherin expression. All 
E-cadherin expressing samples expressed matriptase and 
vice versa. 
subcellular localization to the cell surface 
membrane in Ibc cells
To further study the localization of matriptase 
and c-Met at the subcellular level, the endogenous 
proteins in the IBC line SUM149 were visualized by 
immunocytochemistry and confocal imaging (Figure 2). 
Matriptase and c-Met were mainly expressed on the cell 
surface, as expected, based on the membrane topology 
of both proteins. Analysis of confocal images shows 
extensive localization of both matriptase and c-Met on the 
cell surface membrane with weaker cytoplasmic staining.
Taken together with the results above, matriptase 
and c-Met are co-expressed in the majority of IBC patient 
samples analyzed and localize on the surface of IBC cells. 
Furthermore, the majority of IBC patient samples express 
E-cadherin.
Matriptase silencing abrogates pro-HGF 
mediated c-Met signaling in human Ibc cell 
lines 
To examine the molecular and functional 
relationship between matriptase and c-Met in IBC, we 
employed cell culture models in both 2D and 3D. SUM149 
(ER-/PR-/HER2-) and SUM190 (ER-/PR-/HER2+) cells 
were originally isolated from primary inflammatory 
invasive ductal carcinoma and display characteristics 
commonly found in IBC tumors, including expression of 
E-cadherin [20–23]. 
Analysis of cellular proteins from SUM149 and 
SUM190 by western blotting showed that matriptase and 
c-Met are expressed in both cell lines (Figure 3A, 3A’, 
3B, 3B’ and Supplementary Figure S2) and that stimulation 
with pro-HGF/HGF is required for c-Met activation since no 
phosphorylated c-Met was detected in the absence of pro-
HGF/HGF (Figure 3A’ and 3B’, top panels “No HGF”). Based 
on these characteristics, the two IBC cell lines were deemed 
appropriate for further studies on matriptase/c-Met function.
It has been demonstrated that matriptase can 
cleave and activate the pro-form of HGF [24]. However, 
no studies describing a role for matriptase as a pro-
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HGF activating protease in IBC have been reported. To 
determine whether matriptase regulates c-Met signaling 
via activation of pro-HGF, SUM149 and SUM190 
cells were stimulated with pro-HGF or active HGF and 
the phosphorylation/activation state of c-Met and its 
downstream signaling proteins, Gab1 and AKT, were 
determined by western blot analysis. HGF is secreted 
in its inactive pro-form by stromal cells in both human 
and mice, including stromal mammary fibroblasts and 
macrophages [25-27]. The source of pro-HGF in this 
experimental set-up was human mammary fibroblasts 
expressing pro-HGF [16]. To directly assess the role of 
matriptase for pro-HGF activation, experiments using 
RNAi mediated silencing of matriptase were performed. 
Silencing of matriptase with three independent non-
overlapping synthetic RNA duplexes was achieved in 
SUM149 and SUM190 cells (Figure 3A and 3B). Addition 
of pro-HGF to matriptase sufficient control cells resulted 
in robust activation of c-Met and the downstream targets 
Gab1 and AKT (Figure 3A’ and 3B’, “pro-HGF”). In 
contrast, matriptase silencing led to greatly reduced or 
undetectable levels of c-Met pathway activation in both 
SUM149 and SUM190 cells. Importantly, the matriptase 
silenced cells displayed unaltered activation of c-Met upon 
stimulation with pre-cleaved active HGF, demonstrating 
that the impaired response to pro-HGF is caused by the 
lack of matriptase-mediated cleavage, while the cells 
remain fully HGF/c-Met signaling competent (Figure 3A’ 
and 3B’, second panel, “active HGF”).
To assess the functional consequences of abrogating 
the matriptase-meditated c-Met signaling in IBC cells, a 
proliferation assay was performed. As described above, 
matriptase was silenced in SUM149 with three different 
synthetic RNA duplexes and cells were stimulated with 
pro-HGF or active HGF. As expected, there was no 
significant proliferation difference in matriptase sufficient 
control cells treated with active HGF or pro-HGF. In 
contrast, proliferation in matriptase silenced cells was 
table 1: expression of matriptase, c-Met, and e-cadherin in Ibc patient samples 
sample Id surg/bX treatment Matriptase c-Met e-cadherin
1 S pre-op Chemotherapy + + +
2 S pre-op Chemotherapy + + +
3 S pre-op Chemotherapy + + +
4 S pre-op Chemotherapy + + +
5 S pre-op Chemotherapy + + +
6 S pre-op Chemotherapy + + +
7 S pre-op Chemotherapy + + +
8 S pre-op Chemotherapy + + +
9 S No info − − −
10 S pre-op Chemotherapy + − +
11 S pre-op Chemotherapy + + +
12 S pre-op Chemotherapy + + +
13 BX No treatment + + +
14 S No info + + +
15 S pre-op Chemotherapy + − +
16 S pre-op Chemotherapy + − +
17 S pre-op Chemotherapy + + +
18 BX No treatment + + +
19 S pre-op Chemotherapy + + +
20 S pre-op Chemotherapy + + +
21 S pre-op Chemotherapy + + +
22 BX No treatment + − +
Protein expression of matriptase, c-Met, and E-cadherin determined by IHC. “+” indicates clear expression in the majority 
of cancer cells and “−“indicates no detectable staining above background (compared to serial sections incubated with a non-
immune antibody). “S” indicates that the sample was acquired during surgery and “BX” indicates biopsy acquired sample.
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significantly impaired in response to pro-HGF (Figure 3C, 
white bars) in comparison to the response observed with 
addition of pre-cleaved active HGF (Figure 3C, grey bars).
Matriptase silencing impairs pro-HGF/c-Met 
mediated invasion in human Ibc cells 
The standard 2D cell culture models described 
above are optimal for biochemical analysis of matriptase-
mediated c-Met signaling in IBC. However, additional 
models of IBC are beneficial to study the functional 
importance of this pathway. Breast cancer cells grown 
in 3D cultures are believed to better recapitulate in vivo 
morphology and invasion than cells grown on tissue 
culture plates. SUM149 cells were transiently silenced 
using matriptase RNA duplexes or control duplexes and 
transferred to 3D culture containing growth factor depleted 
reconstituted basement membrane (rBM) (Figure 4). All 
cells formed 3D spheroid structures within 24 hours in this 
model (Figure 4A, 4B, 4D, 4E no HGF). Upon stimulation 
with pro-HGF or active HGF for 24 hours, matriptase 
sufficient control cells displayed pronounced invasive 
growth characterized by branching cellular structures 
and single cells with a flattened spindle-like appearance 
(Figure 4A’, 4D’). In contrast, matriptase silencing 
(Mat KD) rendered the cells unresponsive to pro-HGF 
(Figure 4B’, 4E’), thus, keeping the vast majority of the 
cells confined in compact spheroid structures (Figure 4C). 
Addition of pre-cleaved active HGF restored the ability of 
matriptase-deficient cells to display a similar phenotype 
Figure 1: Matriptase and c-Met protein are co-expressed in Ibc. Representative staining of serial sections of IBC using a 
rabbit anti-matriptase antibody (A, d, H) a rabbit-c-Met antibody (b, e, I) or a mouse anti-E-cadherin antibody (F). Primary antibodies 
were substituted with non-immune IgG as negative controls (c). Matriptase, c-Met, and E-cadherin proteins are primarily localized on 
cell surfaces (brown staining, arrow heads) of invasive epithelia derived IBC cells (indicated with ‘e’) with no significant staining in the 
mesenchymal/stromal compartments (indicated with ‘s’) and display highly similar expression patterns. (G) Expression of matriptase, 
c-Met, and E-cadherin in 22 human IBC cases. Bars depict the frequency of samples expressing matriptase, c-Met, and E-cadherin 
(17/22), matriptase and e-cadherin (4/22), neither protein (1/22), no sample displayed the other expression combinations indicated. (H–I) 
Representative staining for matriptase (H) and c-Met (I) (brown staining, arrow heads) in dermal lymphatic emboli. Both matriptase and 
c-Met are primarily localized on cell surfaces and in the cytoplasm of IBC cells. Tissues were counterstained with haematoxylin (blue/
grey). Scale bars, 50 µm.
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to control cells, suggesting that the c-Met signaling 
pathway remained intact (Figure 4B’’, 4E’’). These data 
demonstrate that matriptase potentiates the invasive 
capacity of IBC cells by activation of pro-HGF. 
Inhibition of matriptase proteolytic activity 
impairs Ibc cell proliferation upon pro-HGF 
stimulation
Based on our findings that matriptase is critically 
involved in IBC cell proliferation and invasion, 
this protease represents a potential target for drug 
development. To determine whether abolishing matriptase 
proteolytic activity would be applicable, we tested a 
matriptase inhibitor, IN-1, in the proliferation assay 
using the SUM 149 and SUM190 lines. IN-1 is highly 
selective for matriptase versus other related proteases 
inclucding hepsin (100-fold), matriptase-2 (300-fold), 
TMPRSS11D (764-fold), thrombin (> 30000-fold), and 
furin (no inhibition) [15]. IN-1 efficiently inhibited the 
proliferative response to pro-HGF in a dose dependent 
manner in both SUM149 cells (Figure 5A, white bars) and 
SUM190 cells (Figure 5B, white bars) with significant 
inhibition observed at 100 nM. No inhibitory effect was 
observed in response to pre-activated HGF, indicating 
that the matriptase-mediated pro-HGF conversion is 
inhibited by IN-1 (Figure 5A, 5B, gray bars). Growth 
inhibition by IN-1 in both cell lines was due to abrogation 
of c-Met activation as demonstrated by western blotting 
(Figure 5C). Matriptase inhibition led to greatly reduced 
(SUM149, 5C upper panels) or undetectable (SUM190, 
5C lower panels) levels of activated c-Met, whereas 
the response to pre-cleaved active HGF was unaltered. 
Together, these results demonstrate that silencing of 
matriptase expression, or inhibition of matriptase 
catalytic activity, leads to decreased pro-HGF activation 
and subsequent c-Met signaling pathway activation, 
ultimately causing impairment of the proliferative and 
invasive response in IBC cells. Also, the results suggest 
that matriptase is a druggable protease that may represent 
a novel target for pharmaceutical intervention in IBC.
dIscussIon
Because of the rarity of IBC and the inherent 
difficulty in obtaining tumor tissue from patients, few 
studies have been performed to map the molecular 
characteristics of this disease. Understanding the distinct 
pathology of IBC and the molecular mechanisms involved 
in the rapid disease progression will likely provide 
insights to aid the discovery of new treatments. The 
present study includes novel expression, mechanistic, and 
Figure 2: Matriptase and c-Met proteins are co-expressed in Ibc cell lines. SUM149 cells were permeabilized and incubated 
with mouse anti-matriptase (M24) and rabbit anti-C-Met, followed by fluorophore-conjugated secondary antibodies. The cells were 
visualized by confocal fluorescence microscopy: Alexa Fluor 488, matriptase (upper left panel); Alexa Fluor 546, c-Met (upper right panel); 
DAPI/matriptase/c-Met merged (lower left panel) and matriptase/c-Met merged (lower right panel). Images were analyzed with VolocityTM 
software. A representative orthogonal section from the original Z-stack was used to assess co-localization (yellow) in XY, XZ, and YZ 
planes. The Y and Z plane views were taken at the position indicated with an open arrow head. Scale bars, 10 µm.
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functional studies of the matriptase/HGF/c-Met epithelial-
mesenchymal protease-mediated signaling axis that may 
represent a future target for therapeutic intervention in 
IBC.
An important component to elucidate the roles 
of matriptase and c-Met in IBC was to determine their 
expression and localization in IBC patient samples. 
Immunohistochemistry studies of serial sections 
demonstrated expression of both matriptase and c-Met in 
infiltrating cancer cells and in the cancer cells of lymphatic 
emboli in the majority of IBC patients. The high frequency 
of c-Met positive samples is in accordance with a previous 
study [28]. Furthermore, matriptase and c-Met are co-
localized on the cell surface in cultured IBC cells.
It has been demonstrated that matriptase can 
cleave and activate the pro-form of HGF which is a 
pleiotropic, paracrine growth factor and key mediator 
of cell migration, proliferation, survival, motility, 
and morphogenesis in epithelial cells [29]. Cleaved, 
activated HGF exerts its effects by binding to the proto-
oncogene tyrosine kinase receptor, c-Met, that elicits pro-
tumorigenic downstream signaling events [29]. Since a 
key post-translational regulation mechanism of HGF/c-
Met signaling is the proteolytic activation of pro-HGF, the 
identification of the physiological activator as a potential 
target for therapeutic intervention in IBC is critical. We 
demonstrate that matriptase regulates c-Met signaling 
via activation of pro-HGF in SUM149 and SUM190 IBC 
Figure 3: Matriptase is essential for activation of the pro-HGF/c-Met signaling pathway and proliferation in Ibc 
cells. RNAi silencing of matriptase in SUM149 cells (A) or SUM190 cells (b) with three independent non-overlapping synthetic RNA 
duplexes (siM1, siM2, and siM3). A %GC matched RNA duplex was used as negative control as well as a mock where no RNA duplex was 
added. (A’, B’) Cells were serum starved and exposed to vehicle, active HGF (2 min), or pro-HGF (15 min) as indicated. Cell lysates were 
separated by SDS-PAGE and analyzed for the presence of activated c-Met and its downstream targets by western blotting. As expected, no 
phosphorylation of c-Met was observed when no HGF was added, whereas addition of pre-cleaved, active HGF resulted in phosphorylation 
of c-Met in all samples. When pro-HGF was added, no phosphorylation of c-Met or its downstream targets, Gab1 and AKT, was observed 
in cells where matriptase was silenced with any of the three RNA duplexes. (c) SUM149 cells were grown on culture plates and matriptase 
was silenced using the three synthetic RNA duplexes mentioned above. The cells were serum starved and left untreated (black bars) or 
exposed to either active HGF (gray bars) or pro-HGF (white bars) for 24  h and counted. Bar graphs show the proliferation at 24 h after 
stimulation (*P < 0.05, **P <0.01). Error bars represent S.D. of triplicates within one assay. Data are representative of four independent 
experiments.
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cells. Functionally, silencing of matriptase expression in 
IBC cells causes severe impairment of proliferation and 
invasion. These findings prompted us to test whether a 
synthetic matriptase inhibitor could inhibit matriptase-
mediated c-Met activation and proliferation. Indeed, the 
IN-1 inhibitor efficiently inhibits proliferation in both IBC 
cell lines with significant inhibition observed at 100 nM. 
It should be mentioned, that two other members of the 
type II transmembrane serine protease family, hepsin and 
TMPRSS13, which have previously been reported as being 
able to cleave and activate pro-HGF in vitro [30–32], 
were readily detectable by western blot analysis in a 
variety of breast cancer cells lines (unpublished data), 
which included the SUM149 and SUM190 lines used in 
this study. Furthermore, HGF activator (HGFA), a soluble 
protease, has been reported to be expressed in multiple 
breast cancer cell lines and in human breast tumors [33]. 
Since no or low residual pro-HGF-activating activity was 
Figure 4: Matriptase mediates pro-HGF induced invasion of Ibc in 3d culture. Matriptase was silenced in SUM149 cells 
(Mat KD) using synthetic RNA duplexes (B, B’, B’’). A %GC matched duplex was used as negative control (A, A’, A’’). Cells formed 
spheroids in 3D rBM overlay culture (A, b) before addition of either pro-HGF (A’, B’) or active HGF (A’’, B’’) and imaged by confocal 
microscopy. Cells were labeled with Cell Tracker Orange and nuclei with Hoechst (blue). When no growth factors were added, control and 
Mat KD spheroids remained intact. In contrast, addition of pro-HGF induced extensive invasive outgrowths in matriptase sufficient control 
cells (A’) whereas the majority of Mat KD spheroids remained intact (B’). Both control and Mat KD spheroids responded to active two-
chain HGF (A’’, B’’). Scale bars, 50 µm (c) 3D rBM cell cultures were scored for the number of intact control spheroids (black bars) and 
intact Mat KD spheroids (white bars) when left untreated or exposed to either active HGF or pro-HGF. Data represent mean of the number 
of intact spheroids before treatment relative to the number after treatment (*P < 0.05). Error bars represent S.D. of triplicates within one 
assay. Data are representative of four independent experiments. (d–e) Low magnification photos of independent experiment performed as 
above. Pro-HGF (D’, E’),  HGF (D’’, E’’), or no growth factor (D, E). When no HGF was added, control and Mat KD spheroids remained 
intact (D, E) (black arrowheads). In contrast, addition of pro-HGF induced extensive scattering and invasion in matriptase sufficient control 
cells (D’) (indicated with open arrowheads) whereas the majority of spheroids in Mat KD cells remained intact (E’). Both control and Mat 
KD responded to active two-chain HGF (D’’, E’’) Scale bars, 200 µm.
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detected upon matriptase silencing, it is unlikely that these 
proteases act as efficient pro-HGF activators on the cell 
surface of IBC cells in the cell culture models used in the 
present study. It cannot be ruled out however, that pro-
HGF is activated by several proteases in IBC in vivo.
The IHC analysis revealed a high frequency of 
samples expressing E-cadherin, which is in agreement 
with previously published studies [20–21]. We have 
previously shown a correlation between matriptase 
and E-cadherin expression in breast cancer cells of 
diverse origin representing a variety of molecular 
subtypes [14]. Thus, matriptase and E-cadherin are 
expressed in IBC cells and in non-IBC cells that have 
preserved epithelial characteristics. Interestingly, neither 
matriptase nor E-cadherin is detectable in cell lines that 
have gained a mesenchymal-like phenotype, with high 
motility and loss of cell–cell adhesion [14]. The loss of 
E-cadherin, with a switch to N-cadherin expression and 
other mesenchymal markers, is considered a hallmark 
of epithelial-to-mesenchymal transition (EMT). Since 
loss of E-cadherin has been shown to promote invasion 
and metastasis in many different carcinomas, it has long 
been considered a paradox that IBC cells, despite their 
aggressiveness, maintain E-cadherin expression in the 
primary tumor and tumor emboli [21]. In fact, it has been 
shown that E-cadherin is overexpressed in IBC and that 
this contributes to the formation of the lymphovascular 
embolus, a cellular structure efficient at metastasis [19]. 
Recent studies have shown that reduced expression of 
E-cadherin leads to a dramatic reduction of the in vivo 
growth capability of IBC tumor cells [21]. The authors 
propose that E-cadherin plays a role in cellular plasticity 
during the reversible processes of EMT and mesenchymal-
to-epithelial transition (MET). Cancer cells retain tight 
control of EMT features such as motility and invasion, 
while maintaining the capacity to display epithelial 
features such as E-cadherin expression to favor tumor 
growth and the establishment of metastatic tumors once 
Figure 5: Inhibition of matriptase proteolytic activity impairs Ibc cell proliferation upon pro-HGF stimulation. 
SUM149 (A) and SUM190 (b) cells were serum starved and IN-1 was added at 10 nM, 100 nM, 1 µM, or 10 µM concomitantly with active 
HGF (gray bars), pro-HGF (white bars), or no growth factors (black bars) for 24 h and cells were counted. In the mock control vehicle 
(PBS) was added. Graphs show the increase in cell numbers at 24 h after stimulation (*P < 0.05, **P < 0.01, ***P < 0.001). Error bars 
represent S.D. of triplicates within one assay. Data are representative of three independent experiments. (c) SUM149 cells (upper panels) 
and SUM190 cells (lower panels) cells were serum starved and pre-incubated with 1 µM IN-1 synthetic matriptase inhibitor for 30 min 
before exposure to either active HGF or  pro-HGF. Cells were lysed at the indicated time points after growth factor exposure and the levels 
of total c-Met and phospho-c-Met were determined by western blotting.
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the cells have reached their site [21]. Our data suggest that 
matriptase, via activation of the c-Met pathway, may be 
a player in this complex regulation of cellular plasticity 
by stimulating both proliferation and invasion of IBC 
cells. Whether matriptase plays additional non-HGF/c-
Met mediated roles in IBC tumorigenicity and whether 
the observed link between expression/loss of matriptase 
and E-cadherin in IBC is correlational or causal in breast 
cancer remains to be explored.
Several drugs that target c-Met, including antibodies 
that bind to c-Met and compete with pro-HGF/HGF 
binding, and c-Met kinase inhibitors have been developed. 
Currently, there are a number of ongoing phase 2 clinical 
trials using various c-Met drugs in patients with TNBC, 
including IBC. Some of the c-Met kinase inhibitors are 
highly selective for c-Met, whereas others target additional 
receptors such as the c-Met-VEGFR-2 inhibitor, XL184 
(cabozantinib), and the cMet-ALK (anaplastic lymphoma 
kinase) inhibitors, X-396 and X-376 (crizotinib). In 
preclinical 3D cell culture models and mouse models 
of TNBC growth, invasion, and metastasis, it was 
demonstrated that cabozantinib significantly inhibits 
TNBC progression and metastasis [34]. It was observed 
that c-Met positive TNBC cells were significantly inhibited 
with cabozantinib, whereas c-Met negative cells were not, 
suggesting that c-Met signaling is the critical pathway in 
this TNBC cell model that is targeted by XL184 treatment 
[34]. Another study assessed the response of IBC cell 
lines to treatment with crizotinib that inhibits c-Met and 
ALK [31]. The majority of IBC patient samples analyzed 
(20/25, 80%) had either increased ALK copy number, low 
level ALK gene amplification, or ALK gene expression. 
Crizotinib was cytotoxic to all ALK expressing cell lines 
tested. In addition, SUM149 cells were also sensitive to 
crizotinib. Since this cell line displays very low levels 
of ALK expression, the authors suggest that the drug 
effect is due to protein kinase inhibition of c-Met [35]. 
Targeting multiple pathways and combining inhibitors 
with different modes of action, including proteases that 
activate tumorigenic growth factors, may circumvent 
resistance to kinase inhibitors [29]. 
 In conclusion, we have demonstrated that targeting 
the pro-HGF activating protease, matriptase, in IBC 
efficiently inhibits pro-oncogenic c-Met signaling, and 
that future studies testing potent and highly selective 
matriptase inhibitors and their potential as novel targeted 
drugs in IBC as well as TNBC may be a promising new 
therapeutic strategy.
MAterIAls And MetHods
Human Ibc tissue
De-identified cases of normal breast tissue and 
inflammatory infiltrating ductal carcinoma were identified 
by a breast surgeon (J.E.L) via the University of Arizona 
Cancer Center Tissue Acquisition and Cellular/Molecular 
Analysis Core. A board certified pathologist verified the 
assignment of IBC versus non-IBC status for all cases by 
inspection of surgical pathology slides and reports. The 
IBC specimens were acquired from a punch biopsy before 
treatment or after neoadjuvant chemotherapy at the time of 
modified radical mastectomy (Table 1). Of the IBC patients, 
36.4% (n = 8/22) were confirmed to have metastatic breast 
cancer as subsequent distant recurrences. Of patients with 
distant metastatic disease, 87.5% (n = 7/8) died of breast 
cancer. 45.4% (n = 10) were lost to follow-up and 1 had 
metastatic non-small cell lung cancer. Only 13.6% (n = 3) 
patients were confirmed not to have metastatic disease after 
5 years of follow-up. The small sample size precludes a 
statistical analysis of matriptase/c-met expression in 
regards to survival, particularly when considering that 
survival outcomes in IBC patients typically is far inferior 
to non-IBC patients. The high rates of loss to follow-up are 
consistent with the fact that University Medical Center is 
a tertiary care referral institution serving a predominantly 
rural, underserved patient population. Patients with IBC, 
a rare disease, were likely to be treated initially at our 
institution but later preferred to complete routine follow-
up care in their own communities. Representative H&E 
stained and 5 unstained slides cut as 3-micron serial 
sections were provided via an IRB approved tissue 
biorepository (#06-0609-04) and transferred to Wayne 
State University for immunohistochemical analysis under 
an approved institutional IRB Exemption (# 2011–156). 
Immunohistochemistry
Tissue slides were deparaffinized with xylene and 
hydrated with graded ethanol solutions. Antigen retrieval 
was performed using citrate buffer, pH 6.0 (Bethyl 
Laboratories, Montgomery, TX) and incubation for 1 h in a 
73°C water bath. The slides were blocked with 2% bovine 
serum albumin in PBS, and immunostained overnight 
at 4°C. Primary antibodies were rabbit anti-matriptase 
(Calbiochem/EMD Millipore, San Diego, CA), rabbit 
anti-c-Met (Leica Microsystems Inc., Buffalo Grove, IL), 
and mouse anti-E-cadherin (Pharmingen/BD Biosciences, 
San Jose, CA). As negative controls, non-immune mouse 
IgG (Sigma, St. Louis, MO) or non-immune rabbit IgG 
(NeoMarkers, Fremont, CA) were used. Bound antibodies 
were visualized using biotin-conjugated anti-rabbit or anti-
mouse (Vector Laboratories, Burlingame, CA) secondary 
antibodies and a Vectastain ABC kit (Vector Laboratories). 
3,3′-diaminobenzidine (DAB) was used as substrate 
(Sigma, St. Louis, MO) and arrays were counterstained 
with hematoxylin. All microscopic images were acquired 
on a Zeiss Scope A.1 using digital imaging.
Human breast cancer cell lines
The SUM149 and SUM190 cell lines were a gift 
from Dr. Stephen Ethier (Medical University of South 
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Carolina, Charleston, SC). SUM149 cells were grown 
in 5% IH media (Ham’s F-12 media, supplemented with 
5% FBS, 1μg/ml hydrocortisone, and 5 μg/ml insulin). 
SUM190 cells were grown in SFIH media (Ham’s F-12 
media, supplemented with 1 μg/ml hydrocortisone, 5 μg/ml 
insulin, 5 mM ethanolamine, 10 mM HEPES, 5 μg/ml 
transferrin, 10 nM triodo-thyronine, 50 μM sodium selenite, 
and 5% BSA).
Immunocytochemistry
SUM149 cells were fixed with 10% neutral-
buffered zinc formalin (Z-fix) (Anatech, Battle Creek, 
MI) for 20 min, blocked in 5% BSA with 0.1% Triton 
X-100 for 1 hr, and incubated with rabbit anti-c-Met 
(Cell Signaling Technology, Beverly, MA) and mouse 
monoclonal anti-matriptase M24 antibody [13] overnight 
at 4°C. The following day, cells were washed with PBS, 
and incubated with anti-rabbit 546 or anti-mouse 488 
antibodies (Invitrogen, Carlsbad, CA) in blocking solution 
for 2 hrs at RT. Cells were washed with PBS and mounted 
with Prolong gold with DAPI (Invitrogen). Confocal 
images were acquired on the Zeiss LSM 780 scope at the 
Microscopy Imaging and Cytometry Resources Core at 
Wayne State University School of Medicine. Images were 
analyzed using VolocityTM software.
rnAi silencing
For matriptase knockdown in SUM149 and SUM190 
IBC cells, three independent Stealth RNAiTM siRNA 
duplexes targeting matriptase (siM1-ST14HSS186125, 
siM2-ST14HSS186126, siM3- ST14HSS110268), as 
well as %GC matched negative controls were used as 
previously described (Invitrogen) [14]. Two days after 
transfection, the cells were serum starved and used in the 
pro-HGF/HGF activation assay, in the 3D invasion assay, 
and in the proliferation assay described below.
Matriptase synthetic inhibitor
A selective, slow, tight-binding inhibitor of 
matriptase containing a ketobenzothiazole serine trap 
(IN-1) was designed based on the auto-catalytic domain 
(RQAR) of matriptase. Details on the synthesis and 
characteristics of the inhibitor have been described 
previously [15]. IN-1 was solubilized in PBS and used at 
concentrations ranging from 10 nM to 10 µM.
Pro-HGF/sF activation assays
Pro-HGF/SF was produced in the immortalized 
human fibroblasts cell line, RMF-HGF, as described 
[16, 17]. In order to estimate the concentration of each 
preparation and ensure quality, western blot analysis was 
performed using a goat anti-HGF primary antibody (R&D 
Systems, Minneapolis, MN) with recombinant human 
recombinant active HGF (R&D Systems) as a standard. 
Human IBC cell lines were plated in 6-well plates, grown 
to confluence, and serum starved for a minimum of 3 hrs. 
The media was then changed to either fresh serum free 
media, serum free media with 100 ng/ml recombinant 
active two-chain HGF (R&D Systems), or pro-HGF with 
or without IN-1. To determine the effect on activation of 
c-Met and the downstream signaling molecules, Gab1 and 
AKT, the cells were lysed in ice cold RIPA lysis buffer 
(150 mM NaCl, 50 mM Tris, 1% NP-40, 0.1% SDS, 
pH 7.4) with protease inhibitor cocktail and Sodium 
Orthovanadate (Sigma). Activation levels of c-Met, Gab1, 
and AKT were determined by assessing the levels of the 
phosphorylated forms relative to the level of the total 
amount of the specific signaling molecules by western 
blot analysis.
Western blot analysis
The protein concentration in cell lysates was 
determined by BCA assay (Pierce, Rockford, IL) and 
lysates were separated by 4–12% reducing SDS-PAGE 
and blotted onto polyvinylidene difluoride (PVDF) 
membranes (Invitrogen). The following primary 
antibodies were used for detection: rabbit anti- matriptase 
(CalBioChem, Philadelphia, PA), rabbit anti-phospho 
cMet (Y1234/1235), anti-phospho Gab1 (y627), anti-
Gab1, anti-phospho AKT (S473), anti-AKT (C73H10), 
mouse anti-human c-Met (25H2) (all from Cell Signaling 
Technology), and mouse anti-beta-actin (Sigma). For 
detection, secondary antibodies conjugated with either 
alkaline phosphatase (Sigma) or horseradish peroxidase 
(Chemicon, Temecula, CA) in combination with either the 
chromogenic substrate nitro-blue tetrazolium and 5-bromo-
4-chloro-3’-indolyphosphate (Roche, Indianapolis, IN) or 
Super-SignalWest Femto Chemiluminescent Substrate 
(Pierce, Rockford, IL) were used. 
3d cell culture
The 3D protocol described in [18] was used. Briefly, 
1 × 104 cells were plated on 12 mm circular cover glasses 
coated with Matrigel Matrix Growth Factor Reduced 
(MMGFR) (BD Biosciences) with serum free Mammary 
Epithelial Cell Growth Medium (MEGM™) media (Lonza, 
Walkersville, MD) containing the BulletKit™ growth 
supplement (BPE, hydrocortisone, GA-1000, Insulin). An 
overlay of MEGM growth media containing 2% MMGFR 
was added 1 hr after seeding. Spheroids were allowed to 
form overnight before addition of 100 ng recombinant HGF 
(R&D Biosystems) or pro-HGF conditioned media for 24 
hrs after which cells were stained with 5 uM Cell Tracker 
Orange (Invitrogen) for 45 min and Hoechst 33342 (Life 
Technologies Carlsbad, CA) for 5 min prior to imaging. 
Confocal images were acquired on the Zeiss LSM 780 
Oncotarget58172www.impactjournals.com/oncotarget
scope at the Microscopy Imaging and Cytometry Resources 
Core at Wayne State University School of Medicine. 
Proliferation assays in human Ibc cell lines 
30,000 IBC cells were seeded in 6-well plates and 
serum starved overnight before stimulation with 100 ng 
active HGF or pro-HGF for 24 h. Cells were then trypsinized 
and recounted using a hemocytometer to determine the cell 
number upon stimulation. In the matriptase inhibition assay 
using IN-1, the synthetic inhibitor was added concomitantly 
with active HGF or pro-HGF. 
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